Modeling microbial drug-resistance: from mathematics to pharmacoeconomics
Complicated intra-abdominal infection (IAI) requires increased health care expenditures and additional resources to compensate for an ineffective starting therapy.Aim. To select the economically optimal algorithm for using antimicrobial agents (AMA) that would minimize the evolving drug-resistance o...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2018-05-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/227 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696816587603968 |
|---|---|
| author | Yu. M. Gomon M. A. Arepyeva Yu. E. Balykina A. S. Kolbin A. A. Kurylev M. A. Proskurin S. V. Sidorenko |
| author_facet | Yu. M. Gomon M. A. Arepyeva Yu. E. Balykina A. S. Kolbin A. A. Kurylev M. A. Proskurin S. V. Sidorenko |
| author_sort | Yu. M. Gomon |
| collection | DOAJ |
| description | Complicated intra-abdominal infection (IAI) requires increased health care expenditures and additional resources to compensate for an ineffective starting therapy.Aim. To select the economically optimal algorithm for using antimicrobial agents (AMA) that would minimize the evolving drug-resistance of microbial flora exemplified by E. coli.Methods. Based on the published data and our own clinical experience with antimicrobial drugs, we calculated the cost of treatment of complicated IAI when either effective or ineffective starting antibiotic therapy was applied. The developing drug-resistance of E. coli was simulated by a mathematical model that incorporated real data on the antimicrobial drugs usage. The model was also able to propose the optimal mode of AMA consumption, which is expected to minimize the microbial drugresistance.Results. According to the model, the current volume of AMA consumption (which includes more than 60% of fluoroquinolones, 3d generation cephalosporins and inhibitor-protected penicillin derivatives) will increase the proportion of the Extended-spectrum betalactamase (ESBL)-positive strains of E. coli by 7% over the next 5 years. In contrast, the proposed alternative (optimized) mode of AMA consumption (almost complete withdrawal of inhibitor-protected penicillins and fluoroquinolones, against an increase in carbapenems by 30% and an increase in 3d generation cephalosporins by 20%), will decrease the proportion of ESBL (+) E. coli strains by 7%. The cost of care of complicated IAI under the current AMA regimen will grow due to the increase in the proportion of ESBL (+) strains of E. coli. In contrast, the alternative (optimal) AMA therapy leading to the decrease in E. coli drug-resistance is expected to reduce the cost of care of complicated IAI to the level where the real and alternative (optimized) AMA consumption expenditures are comparable.Conclusion. The proposed mathematical model allows one to predict the changes in microbial drug-resistance and choose the optimal algorithm of AMA consumption able to restrain the growth of drug-resistance. |
| format | Article |
| id | doaj-art-c13daa54cb534db695ef8f95d80e9b2b |
| institution | DOAJ |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2018-05-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-c13daa54cb534db695ef8f95d80e9b2b2025-08-20T03:19:21ZrusIRBIS LLCФармакоэкономика2070-49092070-49332018-05-01111273610.17749/2070-4909.2018.11.1.027-036207Modeling microbial drug-resistance: from mathematics to pharmacoeconomicsYu. M. Gomon0M. A. Arepyeva1Yu. E. Balykina2A. S. Kolbin3A. A. Kurylev4M. A. Proskurin5S. V. Sidorenko6Pavlov First Sankt-Peterburg State Medical University, Health Ministry of Russian Federation St. Petersburg State Budget Institute of Healthcare “St. George the Martyr City Hospital”Sankt-Peterburg State UniversitySankt-Peterburg State UniversityPavlov First Sankt-Peterburg State Medical University, Health Ministry of Russian Federation Sankt-Peterburg State UniversityPavlov First Sankt-Peterburg State Medical University, Health Ministry of Russian FederationSankt-Peterburg State UniversityFederal State Budget Institution “Childhood Scientific and Clinical Center of Infectious Disease of Federal Medical and Biological Agency” “North-West State Medical University” of the Ministry of Health of the Russian FederationComplicated intra-abdominal infection (IAI) requires increased health care expenditures and additional resources to compensate for an ineffective starting therapy.Aim. To select the economically optimal algorithm for using antimicrobial agents (AMA) that would minimize the evolving drug-resistance of microbial flora exemplified by E. coli.Methods. Based on the published data and our own clinical experience with antimicrobial drugs, we calculated the cost of treatment of complicated IAI when either effective or ineffective starting antibiotic therapy was applied. The developing drug-resistance of E. coli was simulated by a mathematical model that incorporated real data on the antimicrobial drugs usage. The model was also able to propose the optimal mode of AMA consumption, which is expected to minimize the microbial drugresistance.Results. According to the model, the current volume of AMA consumption (which includes more than 60% of fluoroquinolones, 3d generation cephalosporins and inhibitor-protected penicillin derivatives) will increase the proportion of the Extended-spectrum betalactamase (ESBL)-positive strains of E. coli by 7% over the next 5 years. In contrast, the proposed alternative (optimized) mode of AMA consumption (almost complete withdrawal of inhibitor-protected penicillins and fluoroquinolones, against an increase in carbapenems by 30% and an increase in 3d generation cephalosporins by 20%), will decrease the proportion of ESBL (+) E. coli strains by 7%. The cost of care of complicated IAI under the current AMA regimen will grow due to the increase in the proportion of ESBL (+) strains of E. coli. In contrast, the alternative (optimal) AMA therapy leading to the decrease in E. coli drug-resistance is expected to reduce the cost of care of complicated IAI to the level where the real and alternative (optimized) AMA consumption expenditures are comparable.Conclusion. The proposed mathematical model allows one to predict the changes in microbial drug-resistance and choose the optimal algorithm of AMA consumption able to restrain the growth of drug-resistance.https://www.pharmacoeconomics.ru/jour/article/view/227mathematic modelingdrug-resistanceantimicrobial medicationcomplicated intra-abdominal infections |
| spellingShingle | Yu. M. Gomon M. A. Arepyeva Yu. E. Balykina A. S. Kolbin A. A. Kurylev M. A. Proskurin S. V. Sidorenko Modeling microbial drug-resistance: from mathematics to pharmacoeconomics Фармакоэкономика mathematic modeling drug-resistance antimicrobial medication complicated intra-abdominal infections |
| title | Modeling microbial drug-resistance: from mathematics to pharmacoeconomics |
| title_full | Modeling microbial drug-resistance: from mathematics to pharmacoeconomics |
| title_fullStr | Modeling microbial drug-resistance: from mathematics to pharmacoeconomics |
| title_full_unstemmed | Modeling microbial drug-resistance: from mathematics to pharmacoeconomics |
| title_short | Modeling microbial drug-resistance: from mathematics to pharmacoeconomics |
| title_sort | modeling microbial drug resistance from mathematics to pharmacoeconomics |
| topic | mathematic modeling drug-resistance antimicrobial medication complicated intra-abdominal infections |
| url | https://www.pharmacoeconomics.ru/jour/article/view/227 |
| work_keys_str_mv | AT yumgomon modelingmicrobialdrugresistancefrommathematicstopharmacoeconomics AT maarepyeva modelingmicrobialdrugresistancefrommathematicstopharmacoeconomics AT yuebalykina modelingmicrobialdrugresistancefrommathematicstopharmacoeconomics AT askolbin modelingmicrobialdrugresistancefrommathematicstopharmacoeconomics AT aakurylev modelingmicrobialdrugresistancefrommathematicstopharmacoeconomics AT maproskurin modelingmicrobialdrugresistancefrommathematicstopharmacoeconomics AT svsidorenko modelingmicrobialdrugresistancefrommathematicstopharmacoeconomics |